GRCE · XBRL financial data

Grace Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GRCE's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Revenue	—	100,000	—	—	—	—
Cost of goods and services sold	76	0	—	—	—	—
Research and development	4,173	5,559	9,972	4,683	9,511	2,405
General and administrative	5,521	9,263	7,614	6,432	7,168	8,672
Operating income (loss)	(16,419)	(15,589)	(52,155)	(12,852)	(16,679)	(11,077)
Interest income	107	77	246	911	711	685
Income tax expense (benefit)	0	(648)	(9,542)	(1,832)	(3,199)	(1,700)
Net income (loss)	(19,678)	(9,819)	(42,429)	(12,853)	(9,568)	(7,793)
Earnings per share, basic USD per share	—	(0.27)	(0.95)	(1.35)	(0.79)	(0.47)
Earnings per share, diluted USD per share	—	(0.27)	(0.95)	(1.35)	(0.79)	(0.47)
Weighted average shares, basic thousands of shares	—	36,842	44,613	9,529	12,087	16,511
Weighted average shares, diluted thousands of shares	—	36,842	44,613	9,529	12,087	16,511

Fiscal years (GRCE's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	50,942	30,339	27,875	23,005	22,133	16,977
Short-term investments	9,789	13,322	15	0	—	—
Marketable securities	9,789	—	—	—	—	—
Accounts receivable	530	548	802	722	—	—
Total current assets	62,372	45,531	29,290	24,010	22,712	17,380
Property and equipment, net	—	20,890	12,198	24	15	8
Right-of-use asset	86	315	463	0	—	—
Goodwill	—	12,964	8,138	8,138	8,138	8,138
Total assets	62,458	128,620	79,123	73,300	71,993	66,654
Accrued liabilities	607	296	946	176	—	—
Total current liabilities	1,579	3,260	3,411	1,684	1,930	2,146
Lease liability, non-current	—	191	410	0	—	—
Total liabilities	6,798	20,350	11,168	11,557	5,383	2,758
Accumulated deficit	(146,018)	(155,837)	(198,266)	(211,119)	(220,687)	(228,480)
Total stockholders' equity	55,660	108,270	67,955	61,743	66,610	63,896
Total liabilities and equity	62,458	128,620	79,123	73,300	71,993	66,654
Common shares outstanding (cover page) thousands of shares	208,376	44,440	44,613	9,399	13,829	16,274

Fiscal years (GRCE's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	(19,678)	(9,819)	(42,429)	(12,853)	(9,568)	(7,793)
Stock-based compensation	1,174	1,337	1,811	913	730	798
Net cash from operating activities	(14,319)	(17,234)	(15,913)	(12,333)	(14,904)	(8,869)
Net cash from investing activities	(9,858)	(3,522)	13,153	104	0	0
Proceeds from issuing common stock	59,332	0	304	0	—	—
Net cash from financing activities	59,490	0	304	7,359	14,032	3,713
Net change in cash	36,702	(20,603)	(2,464)	(4,870)	(872)	(5,156)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Grace Therapeutics	13,756	not reported	(3,221)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026
Annovis Bio	18,729	0*	(21,914)*	42.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	32	not reported	(244)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Karyopharm Therapeutics	54,980	33,432	(24,931)*	22.7M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Kezar Life Sciences	66,229	not reported	(7,445)	7.4M	8.9 quarters	Q1 FY26 10-QMar 31, 2026
BriaCell Therapeutics	9,852	not reported	(5,959)*	8.7M	3.4 quarters	Q4 FY26 10-KJul 31, 2026
Insight Molecular Diagnostics	17,756	239	(9,268)*	32.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Rein Therapeutics	8,542	0	(8,640)*	86.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.